Menu ×

HEALTHCARE & PHARMACEUTICAL

Methotrexate Drug Market Segmentation By Type (2.5mg/ml and 2mg/ml); By Route of Administration (Intravenous and Oral); By Application (Cancer, Autoimmune Diseases, Ectopic Pregnancy, and Others); By End Users (Hospitals, Homecare, Specialty Clinics, and Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) - Global Demand Analysis & Opportunity Outlook 2028

  • Text Size:

Extensive insights into the Growth of Methotrexate Drug Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More
IN THE NEWS
  • June 2, 2020: Pfizer Inc., a reputed leader in the healthcare sector,  invited its investors, and the general public to a webcast organized by them, and it will include a discussion with their Chairman and Chief Executive Officer, Albert Bourla. This event is scheduled for the Goldman Sachs 41st Annual Global Healthcare Conference, happening on Tuesday, June 9, 2020.
  • May 3, 2018: Hikma Pharmaceuticals announced the arrival of Methotrexate for Injection, USP in a 1g preservative-free presentation, and Methotrexate Injection, USP 50mg/2mL, 2 mL vials produced by their wholly-owned US subsidiary West-Ward Pharmaceuticals Corp., in order to curb the shortage of this product in the US region.

Methotrexate  Drug Market Overview

Methotrexate (MTX) is a drug that acts as a chemotherapy agent, thus used for cancer treatments and as an immune system suppressant, hence it is also prevailing for the treatment of autoimmune diseases. Along with that, methotrexate drug is widely known for its role in treating medical abortions and ectopic pregnancy. It can be injected into the veins or can be taken orally and the drug is approved by the FDA.

Market Size and Forecast

The methotrexate drug market is expected to observe an attainable high CAGR during the forecast period, i.e., 2020-2028. The market is segmented by type, route of administration, application, end-users, distribution channel, and region. Among distribution channel segmentation, the hospital pharmacies segment is anticipated to grow significantly during the forecast period on account of growing numbers of registered cancer & autoimmune diseased patients worldwide, the prevalence of medical abortions, growing awareness about cancer diseases, and R&D initiatives resulting in advanced medications and drugs to cure the illness.

Growth Drivers

Growing awareness related to associated diseases and less toxicity compared to other treatments

An increase in the incidence of target diseases and rising awareness among the healthcare sector and the common public related to the drug, are the key factors that are driving the growth of the global methotrexate drug market.

Methotrexate was widely accepted among healthcare professionals for treating cancer as it was less toxic than the then used treatments. It has extensive use while performing chemotherapies on patients and in disease-modifying treatments for autoimmune illnesses. For its effectiveness, low-dose methotrexate is often preferred for first-line therapy of rheumatoid arthritis. The drug is widely popular for terminating pregnancies during the early stages and for treating ectopic pregnancies. CLICK TO DOWNLOAD SAMPLE REPORT
According to WHO, Cancer is the second foremost cause of death globally and is accountable for a probable 9.6 million deaths in 2018. Worldwide, about 1 in 6 deaths is owed to cancer.

Furthermore, initiatives taken by numerous government and private organizations to spread alertness about the target diseases, rise in disposable income and surge in healthcare facilities in developing countries, novel R&D inventiveness to create medications, technological innovations, and investments by major players are likely to boost the market growth during the forecast period.

Restraints

Side effects caused by the drug

Common side effects of consuming methotrexate might include hair loss, nausea, headaches, and skin pigmentation. The most common side effects which can have adverse effects include liver damage, kidney failure, and others. These effects might come up as market hindrances in the foreseeable future.

Further, strict government regulations in certain nations, lack of awareness, slow detection of the disease, and high costs involved in the treatments might also add as growth constraints for the overall methotrexate drug market.

Market Segmentation

Our in-depth analysis of the Methotrexate  Drugmarket includes the following segments:

By Type

  • 2.5mg/ml
  • 2mg/ml

By Route Of Administration

  • Oral
  • Intravenous

By Application

  • Cancer 
    • Breast Cancer
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Gestational Trophoblastic Disease
    • Osteosarcoma 
  • Autoimmune Diseases
    • Psoriasis
    • Rheumatoid Arthritis
    • Crohn's Disease
    • Others
  • Ectopic Pregnancy
  • Others

By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region

Geographically, the methotrexate drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.

North America is projected to hold the largest market share during the forecast period. The dominance is attributed to factors such as high healthcare expenditure, a high rate of adoption of innovative technology, a rise in the prevalence of target diseases, and a favorable pipeline. Further, the ease of availability of methotrexate drug therapies, rise in R&D concerning methotrexate drugs, various campaigns regarding cancer survivors, and the availability of reimbursements are further contributing towards the regional growth.

Europe is expected to be the second-largest market for methotrexate drugs owing to aspects such as rising government expenditure on the healthcare industry, new product take-offs, product authorizations by the government, and the effort of the companies to develop technically advanced products.

Asia-Pacific is estimated to grow at the fastest rate during the forecast period owing to various aspects such as growth in the occurrence of disorders requiring methotrexate drug, a surge in the number of cancer patients, increased female population needing medical abortions, upsurge in healthcare expenditure, penetration of leading players, burgeoning population, and a rise in disposable revenue.

According to WHO, around 70% of deaths from cancer take place in low- and middle-income nations.

Latin America and the Middle East and Africa are projected to experience scalable heights in the foreseeable future as a result of efforts made by the governments in these regions to promote the use of medications and spread the awareness about the health disorders.

According to The International Agency for Research on Cancer (IARC),  a part of the World Health Organization, America has 13.3% of the worldwide population and holds for 21.0% of cancer occurrences, and 14.4% of cancer mortality universally. Europe books 23.4% of the global cancer incidences and 20.3% of the cancer deaths, even though it has only 9.0% of the global populace. Whereas, approximately half of the novel cases and more than half of cancer demises worldwide in 2018 were projected to occur in Asia, in part since the region has nearly 60% of the global populace. These estimates were released on September 12, 2018.

The methotrexate drug market is further classified based on region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • the Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis.

Top Featured Companies Dominating The Market


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2020 Research Nester. All Rights Reserved